Predicting the response to sumatriptan: The Sumatriptan Naratriptan Aggregate Patient database

Neurology

Volumn 63, Issue 3, 2004, Pages 520-524

  Christoph Diener, Hans ^a   Ferrari, Michel ^b   Mansbach, Hank ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARATRIPTAN; PLACEBO; SUMATRIPTAN;

ADULT; ARTICLE; BED REST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; OPEN STUDY; OUTCOMES RESEARCH; PAIN; PHOTOPHOBIA; PHYSICAL DISABILITY; PREDICTION; PRIORITY JOURNAL; PULSATILE FLOW; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE; STATISTICAL ANALYSIS; VOMITING;

EID: 3543111437     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000133207.70312.30     Document Type: Article

References (16)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-657.
2. Schoenen J. Acute migraine therapy - The newer drugs. Curr Opin Neurol 1997;10:237-243.
3. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Invest Drugs 2001;10:1831-1845.
4. Litaker DG, Solomon GD, Genzen JR. Using pretreatment quality of life perceptions to predict response to sumatriptan in migraineurs. Headache 1998;37:630-634.
5. Sheftell F, O'Quinn S, Watson C, et al. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000;40:103-110.
6. Sanchez del Rio M, Silberstein S. How to pick optimal acute treatment for migraine headache. Cur Pain Headache Rep 2001;5:170-178.
7. Headache Classification Committee of the International Headache Society. Classification of headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
8. Diener H-C on behalf of the SNAP Database Study Group. Factors predicting headache response to placebo in migraine attacks: results from the Sumatriptan Naratriptan Aggregate Patient (SNAP) database. Cephalalgia 2001;21:414. Abstract.
9. Barrows C, Saunders W, Austin SR, et al. The aggregation and analysis of the SNAP (Sumatriptan Naratriptan Aggregate Patient) database. Cephalalgia 2001;21:442. Abstract.
10. Cady RK, Lipton RB, Hall C, et al: Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum Study. Headache 2000;40:792-797.
11. Cady RK, Sheftell F, Lipton RB, et al. Effects of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000;22:1035-1048.
12. Lipton RB, Mansbach H, for the SNAP Database Study Group. Effect of treatment when pain is mild on the efficacy of sumatriptan tablets in migraine: data from the Sumatriptan Naratriptan Aggregate Patient (SNAP) database. Manuscript in preparation.
13. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia. Ann Neurol 2004;55:19-26.
14. Anthony M, Rasmussen BK. Migraine without aura. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. Chapter 34. New York: Raven Press, 1993;255-262.
15. Silberstein SD. Headache and female hormones: what you need to know. Curr Opin Neurol 2001;14:323-333.
16. Case AM, Reid RL. Menstrual cycle effects on common medical conditions. Comp Ther 2001;27:65-71.